Clinical trials: Recurrent Venous Thromboembolism
Venous Thromboembolism, Deep Vein Thrombosis (DVT)
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism
- Trial name
- NCT00986154
- Testing
- edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
- Where
- 454 sites in United States, Argentina and 36 more
- Volunteers
- 8,292 people
- Sponsor
- Daiichi Sankyo
Pulmonary Embolism, Thromboembolism
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of…
- Conditions
- Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis
- Trial name
- EinsteinChoice (NCT02064439)
- Testing
- BAY 59-7939, ASA
- Where
- 266 sites in United States, Australia and 29 more
- Volunteers
- 3,365 people
- Sponsor
- Bayer
Venous Thromboembolism
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
The primary efficacy objective is to evaluate whether dabigatran etexilate is superior to placebo in the long-term prevention of recurrent symptomatic venous thrombo-embolism (VTE) in patients with symptomatic deep-vein…
- Trial name
- RE-SONATE (NCT00558259)
- Testing
- dabigatran etexilate 150 mg twice daily (BID)
- Where
- 147 sites in United States, Australia and 19 more
- Volunteers
- 1,353 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
- Trial name
- NCT05966740
- Where
- 10 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Deep Vein Thrombosis, Pulmonary Embolism
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
Design: U.S.-based, single-center, randomized placebo-controlled trial. Brief Treatment Description: Low-intensity apixaban (2.5mg twice daily) for extended-duration secondary prevention of VTE after initial treatment for…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- HI-PRO (NCT04168203)
- Testing
- Apixaban 2.5 MG
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Brigham and Women's Hospital
Venous Thromboembolism
Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study
This is a multicenter, randomized, double-blind, placebo-controlled, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (deep vein thrombosis) or PE (pulmonary embolism) who completed 6 or 12…
- Trial name
- NCT00439725
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 322 sites in United States, Australia and 31 more
- Volunteers
- 1,197 people
- Sponsor
- Bayer
Vascular Diseases, Embolism and Thrombosis
Epidemiology of Thromboembolism Disease: A Cohort Study
The purpose of this study is to determine different risk factors of thromboembolic disease. Different points will be studied 1. do different types of thromboembolic disease (distal Deep Vein Thrombosis (DVT), proximal DVT…
- Conditions
- Vascular Diseases, Embolism and Thrombosis, Phlebitis, Venous Insufficiency
- Trial name
- OPTIMEV (NCT00670540)
- Testing
- procedure of Deep Vein Thrombosis (DVT) and PE (Pulmonary Embolism) diagnosis
- Where
- 231 sites in Belgium, France and 1 more
- Volunteers
- 8,256 people
- Sponsor
- University Hospital, Grenoble
Venous Thromboembolism
D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism
Optimal duration of oral anticoagulant therapy in patients with recurrent episodes of venous thromboembolism (VTE) is a matter of debate and recommendations are based on inadequate evidence.
- Trial name
- NCT00428441
- Testing
- Warfarin
- Where
- Italy
- Volunteers
- 73 people
- Sponsor
- Università degli Studi dell'Insubria
Thromboembolic Disease Recurrent, Deep Vein Thrombosis
Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis (PREDICTORS)
Patients with a history of blood clots are at risk of developing additional clots in the future. Doctors use a tool called a clinical decision rule to tell them how likely it is that a patient has a blood clot and if they should…
- Conditions
- Thromboembolic Disease Recurrent, Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- PREDICTORS (NCT02297373)
- Where
- 9 sites in Canada, Netherlands and 1 more
- Volunteers
- 744 people
- Sponsor
- Ottawa Hospital Research Institute